|
ZHX1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.48660031138593E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.44119996123993E-09 |
| Normal-vs-Stage2 |
2.855900E-03 |
| Normal-vs-Stage3 |
8.32140001350012E-09 |
| Normal-vs-Stage4 |
5.35639999021953E-09 |
| Stage1-vs-Stage2 |
1.095240E-01 |
| Stage1-vs-Stage3 |
3.959400E-01 |
| Stage1-vs-Stage4 |
1.282960E-01 |
| Stage2-vs-Stage3 |
4.404200E-02 |
| Stage2-vs-Stage4 |
1.312270E-02 |
| Stage3-vs-Stage4 |
4.116600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.26820023768926E-10 |
| Normal-vs-AfricanAmerican |
5.462900E-03 |
| Normal-vs-Asian |
2.00699999952647E-07 |
| Caucasian-vs-AfricanAmerican |
2.977800E-01 |
| Caucasian-vs-Asian |
7.548000E-01 |
| AfricanAmerican-vs-Asian |
2.534600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.54240000005812E-07 |
| Normal-vs-Female |
5.72640046492268E-10 |
| Male-vs-Female |
6.630600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.10400000030708E-07 |
| Normal-vs-Age(41-60Yrs) |
5.13070030905283E-10 |
| Normal-vs-Age(61-80Yrs) |
3.70290000000217E-05 |
| Normal-vs-Age(81-100Yrs) |
2.850000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.685800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.952400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.378800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.423900E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.368600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.419600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.522990E-01 |
| Classical-VS-Follicular |
1.809540E-02 |
| Classical-VS-Other |
4.275000E-01 |
| Classical-VS-Normal |
1.37389999377291E-09 |
| Tall-VS-Follicular |
4.285000E-03 |
| Tall-VS-Other |
3.035200E-01 |
| Tall-VS-Normal |
1.62569999684337E-08 |
| Follicular-VS-Other |
9.957000E-01 |
| Follicular-VS-Normal |
9.173400E-04 |
| Other-VS-Normal |
1.167210E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.30820004513077E-09 |
| Normal-vs-N1 |
2.10600004102446E-09 |
| N0-vs-N1 |
5.588100E-02 |
|
|
